ArticleDiscover oncology2025
Clinicopathological characteristics and prognostic factors of invasive micropapillary carcinoma of the breast.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeTo evaluate the clinicopathological characteristics of breast invasive micropapillary carcinoma (IMPC) and identify factors associated with recurrence and metastasis.
methodsThe study retrospectively analyzed 401 cases of breast IMPC diagnosed between 2017 and 2021. The primary endpoint was recurrence and metastasis-free survival (RMFS). Secondary endpoints included locoregional recurrence-free survival (LRRFS) and distant metastasis-free survival (DMFS). Survival was estimated using the Kaplan-Meier method and compared with the log-rank test. Univariable and multivariable Cox regression analyses were performed to identify prognostic factors. Continuous variables were categorized using maximum log-rank statistics to optimize group stratification.
resultsThe median follow-up duration was 46.9 months (range, 1-92 months). The 5-year RMFS, LRRFS and DMFS rates were 86.0% (95% CI, 82.2%-90.0%), 97.5% (95% CI, 95.8%-99.3%) and 86.5% (95% CI, 82.8%-90.5%), respectively. Multivariable Cox analysis showed that maximum tumor diameter (≤ 1.7 cm vs. >1.7 cm, P = 0.018), the log odds of positive lymph nodes (LODDS) (≤ 0 vs. >0, P = 0.008), histological grade (I-II vs. III, P = 0.002), and receipt of neoadjuvant chemotherapy (P = 0.003) were independent predictors of recurrence and metastasis.
conclusionBreast IMPC carries a relatively high risk of recurrence and metastasis. Tumor size, LODDS, histologic grade, and neoadjuvant chemotherapy were independently associated with outcomes, underscoring the need for closer clinical monitoring and refined risk stratification in this subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.